Life Extension Final Clerance Sale

Life Extension Magazine

LE Magazine April 2006
image

A Natural Approach to Menopause

By Dale Kiefer

Cancer-Preventive Cruciferous Vegetables

Epidemiological evidence strongly suggests that abundant consumption of cruciferous vegetables such as broccoli, from the Brassica genus, correlates with lower breast cancer incidence. A recent study in China concluded: “Greater Brassica vegetable consumption . . . was associated with significantly reduced breast cancer risk among Chinese women.87

The bioactive chemicals in cruciferous vegetables that are responsible for cancer protection derive from a family of chemicals called gluco-sinolates. When consumed, gluco-sinolates are converted to highly beneficial compounds, including sulforaphane and indole-3-carbinol (I3C). These compounds are believed to inhibit numerous types of cancers, including breast and cervical cancers, by a variety of mechanisms.88,89 In a recent article published in the Journal of Nutritional Biochemistry, scientists noted: “Mounting preclinical and clinical evidence indicates that indole-3-carbinol (I3C), a key bioactive food component in cruciferous vegetables, has multiple anticarcinogenic and anti-tumorigenic properties.”90

I3C appears especially effective in protecting against hormone-dependent cancers such as breast, cervical, and prostate cancers, due to its favorable influence on the body’s balance of estrogens.91-95 I3C further affects health by undergoing a natural conversion in the body to yet another potent anti-cancer compound, diindolylmethane (DIM). In addition to stopping hormone-dependent cancer cells in their tracks, DIM inhibits breast cancer cells that are not hormone dependent, through a number of mechanisms.

For example, scientists at the University of California, Berkeley, recently discovered that DIM causes breast cancer cells to boost production of interferon gamma, an immune system component that plays an important role in preventing the development of primary and transplanted tumors.96 This finding is only the latest in a long line of discoveries regarding the healing properties of cruciferous vegetables. It is likely that researchers will continue to unravel the many ways in which cruciferous vegetable compounds work to prevent and destroy different types of cancer.

HORMONES USED IN MENOPAUSE MANAGEMENT

Estrogens. Estriol is the main component of bioidentical estrogen replacement therapy, often used with smaller proportions of estradiol and estrone. Estriol offers many of the benefits of more conventional estrogen-replacement therapies, without the harsh side effects or long-term dangers associated with conventional hormone replacement therapy.97

Some popular prescription estrogen formulas are BiEst and TriEst. BiEst consists of estradiol and estriol, while TriEst contains all three estrogens.98

Progesterone is important to hormone replacement, serving as a counterpoint to estrogen. One of progesterone’s most valuable benefits may be its ability to fight cancer. Studies have shown that progesterone has anti-proliferative effects on at least two different types of breast cancer cells.99 Natural progesterone has also demonstrated neuroprotective properties.100 Progesterone deficiency has been linked to migraine.101

Most natural progesterone products are derived from soybeans and yams, and can be purchased over the counter. A common form of natural progesterone is dispensed in a cream that is applied topically to the skin.102,103 Many physicians recommend using progesterone therapy only during the last half of the month to simulate a young, healthy progesterone cycle.

DHEA is a hormone secreted by the adrenal gland, the gonads, and the brain.104 Although women usually have less DHEA than men, both sexes lose DHEA at about the same rate, suggesting that its decline is related to aging.105,106 Decreased levels of DHEA are associated with cancer, diabetes, lupus, and psychiatric illness.107,108

DHEA has been shown to improve mood, neurological functions, immune function, energy, and feelings of well-being, and to maintain muscle and bone mass.109-111 One study demonstrated DHEA and pregnenolone help enhance memory.112 DHEA may also improve insulin sensitivity and lower triglyceride levels.113

Testosterone levels gradually decrease with age.114 Loss of testosterone adversely affects libido, bone and muscle mass, vasomotor symptoms, cardiovascular health, mood, and well-being.115,116 Testosterone therapy, combined with estrogen therapy, has been shown to improve quality of life, vigor, mood, ability to concentrate, bone mineralization, libido, and sexual satisfaction.117-120 This combination therapy also produces improvements in hot flashes, sleep disturbances, night sweats, and vaginal dryness. In women, DHEA often converts to testosterone, thereby making it possible to raise testosterone levels using DHEA supplements.114,119

Pregnenolone levels likewise decline with age, decreasing significantly in women after the age of 30.121 Reduced pregnenolone levels result in decreased amounts of all other hormones, and pregnenolone deficiencies have been associated with diminished brain function and dementia.122,123

Conclusion

Menopause marks an important life transition for women, one potentially fraught with challenges to health and quality of life.

While many women wish to avoid the risks associated with estrogen drugs, they are keenly interested in finding relief from hot flashes, depression, irritability, insomnia, breast pain, and possible declines in cognition and bone and cardiovascular health.

Fortunately, the wisdom of ancient folk medicine combined with the objective application of modern science may now help women obtain effective, reliable relief from these menopausal conditions, without significant side effects.

HORMONE REPLACEMENT THERAPY, THEN AND NOW

For decades, hormone replacement therapy was essentially the standard treatment for menopausal complaints. This changed abruptly in 2002, when the National Institutes of Health announced that it had halted a comprehensive study of the effects of hormone replacement therapy on various aspects of women’s long-term health.

Alarmed by emerging findings, researchers cancelled the massive trial, known as the Women’s Health Initiative, before it was completed. Although the combination of estrogen and progestin improved healthy menopausal women’s bone health compared to placebo, it was also clearly associated with significant increases in heart disease, stroke, blood clots, and breast cancer. Hormone replacement therapy increased the incidence of breast cancer alone by as much as 26%, while increasing heart attack incidence by nearly 30%.1

Accordingly, menopausal women were encouraged to discontinue hormone replacement therapy, and millions of women complied.124 Although hormone replacement therapy offers slight improvements in osteoporosis risk and incidence of colon cancer, NIH officials noted, “The balance of harm versus benefit does not justify any woman beginning or continuing to take estrogen plus progestin.” While the use of hormone replacement therapy has dropped precipitously, the health problems associated with menopause remain. What to do about the erosion of quality of life, sleeplessness, irritability, hot flashes, and brittle bones that accompany menopause? Data indicate that women have been reluctant to turn to traditional herbal remedies such as black cohosh and soy.124

However, mounting evidence suggests that women should embrace these time-honored remedies, as science makes progress in proving what traditional healers have long known: botanicals work. Indeed, nature seems to know best, offering all the benefits of hormone replacement therapy with few, if any, of the side effects. Herbal remedies in use for centuries are gradually regaining acceptance in the wake of hormone replacement therapy’s fall from grace.

References

1. Available at: www.nhlbi.nih.gov/new/ press/02-07-09.html. Accessed February 2, 2006.

2. Wietrzyk J, Grynkiewicz G, Opolski A. Phytoestrogens in cancer prevention and therapy—mechanisms of their biological activity. Anticancer Res. 2005 May;25(3c):2357-66.

3. Tang GW. The climacteric of Chinese factory workers. Maturitas. 1994 Oct;19(3):177-82.

4. Lissin LW, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol. 2000 May;35(6):1403-10.

5. Kim MK, Chung BC, Yu VY, et al. Relationships of urinary phyto-oestrogen excretion to BMD in postmenopausal women. Clin Endocrinol (Oxf). 2002 Mar;56(3):321-8.

6. Fugate SE, Church CO. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother. 2004 Sep;38(9):1482-99.

7. Geller SE, Studee L. Botanical and dietary supplements for menopausal symptoms: what works, what does not. J Womens Health (Larchmt.). 2005 Sep;14(7):634-49.

8. Seeram NP, Adams LS, Henning SM, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 2005 Jun;16(6):360-7.

9. Kim ND, Mehta R, Yu W, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat. 2002 Feb;71(3):203-17.

10. Mehta R, Lansky EP. Breast cancer chemopreventive properties of pomegranate (Punica granatum) fruit extracts in a mouse mammary organ culture. Eur J Cancer Prev. 2004 Aug;13(4):345-8.

11. Chidambara Murthy KN, Jayaprakasha GK, Singh RP. Studies on antioxidant activity of pomegranate (Punica granatum) peel extract using in vivo models. J Agric Food Chem. 2002 Aug 14;50(17):4791-5.

12. Sudheesh S, Vijayalakshmi NR. Flavonoids from Punica granatum—potential antiperoxidative agents. Fitoterapia. 2005 Mar;76(2):181-6.

13. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001 Jan 20;322(7279):134-7.

14. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)—pharmacology and clinical indications. Phytomedicine. 2003 May;10(4):348-57.

15. Roemheld-Hamm B. Chasteberry. Am Fam Physician. 2005 Sep 1;72(5):821-4.

16. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer C, Birkhauser M. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas. 2005 Aug 16;51(4):397-404.

17. Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. 2005 May;105(5 Pt 1):1074-83.

18. Branca F, Lorenzetti S. Health effects of phytoestrogens. Forum Nutr. 2005;(57):100-11.

19. Linseisen J, Piller R, Hermann S, Chang-Claude J. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int J Cancer. 2004 Jun 10;110(2):284-90.

20. McCann SE, Muti P, Vito D, et al. Dietary lignan intakes and risk of pre- and postmenopausal breast cancer. Int J Cancer. 2004 Sep 1;111(3):440-3.

21. Saleem M, Kim HJ, Ali MS, Lee YS. An update on bioactive plant lignans. Nat Prod Rep. 2005 Dec;22(6):696-716.

22. Wang LQ. Mammalian phytoestrogens: enterodiol and enterolactone. J Chromatogr B Analyt Technol Biomed Life Sci . 2002 Sep 25;777(1-2):289-309.

23. Kreijkamp-Kaspers S, Kok L, Bots ML, Grobbee DE, van der Schouw YT. Dietary phytoestrogens and vascular function in postmenopausal women: a cross-sectional study. J Hypertens. 2004 Jul;22(7):1381-8.

24. Franco OH, Burger H, Lebrun CE, et al. Higher dietary intake of lignans is associated with better cognitive performance in postmenopausal women. J Nutr. 2005 May;135(5):1190-5.

25. Saarinen NM, Huovinen R, Warri A, et al. Uptake and metabolism of hydroxymatairesinol in relation to its anticarcinogenicity in DMBA-induced rat mammary carcinoma model. Nutr Cancer. 2001;41(1-2):82-90.

26. Saarinen NM, Penttinen PE, Smeds AI, Hurmerinta TT, Makela SI. Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):209-19.

27. Katsuda S, Yoshida M, Saarinen N, et al. Chemopreventive effects of hydroxymatairesinol on uterine carcinogenesis in Donryu rats. Exp Biol Med (Maywood). 2004 May;229(5):417-24.

28. Kangas L, Saarinen N, Mutanen M, et al. Antioxidant and antitumor effects of hydroxymatairesinol (HM-3000, HMR), a lignan isolated from the knots of spruce. Eur J Cancer Prev. 2002 Aug;11 Suppl 2S48-S57.

29. Saarinen NM, Warri A, Makela SI, et al. Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies). Nutr Cancer. 2000;36(2):207-16.

30. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004 Jun;23(3):423-33.

31. Fuhrman B, Volkova N, Aviram M. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem. 2005 Sep;16(9):570-6.

32. Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):221-36.

33. Kim ND, Mehta R, Yu W, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat. 2002 Feb;71(3):203-17.

34. Cornwell T, Cohick W, Raskin I. Dietary phytoestrogens and health. Phytochemistry. 2004 Apr;65(8):995-1016.

35. Holzbeierlein JM, McIntosh J, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Curr Opin Urol. 2005 Jan;15(1):17-22.

36. Singeltary KW, Frey RS, Li JY. Differential effects of genistein cell proliferation, cyclin B1, and p34cdc2 in transformed and nontransformed human breast cells. Pharm Biol. 2002;40:35-42.

37. Jeune MA, Kumi-Diaka J, Brown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J Med Food. 2005;8(4):469-75.

38. Frey RS, Li J, Singletary KW. Effects of genistein on cell proliferation and cell cycle arrest in nonneoplastic human mammary epithelial cells: involvement of Cdc2, p21(waf/cip1), p27(kip1), and Cdc25C expression. Biochem Pharmacol. 2001 Apr 15;61(8):979-89.

39. Rowell C, Carpenter DM, Lamartiniere CA. Chemoprevention of breast cancer, proteomic discovery of genistein action in the rat mammary gland. J Nutr. 2005 Dec;135(12 Suppl):2953S-9S.

40. de Kleijn MJ, van der Schouw YT, Wilson PW, Grobbee DE, Jacques PF. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal US women: the Framingham study. J Nutr. 2002 Feb;132(2):276-82.

41. Hedelin M, Klint A, Chang ET, et al. Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate sweden study (sweden). Cancer Causes Control. 2006 Mar;17(2):169-80.

42. Xu WH, Zheng W, Xiang YB, et al. Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study. BMJ. 2004 May 29;328(7451):1285.

43. Sarkar FH, Li Y. Cell signaling pathways altered by natural chemopreventive agents. Mutat Res. 2004 Nov 2;555(1-2):53-64.

44. Sarkar FH, Li Y. The role of isoflavones in cancer chemoprevention. Front Biosci. 2004 Sep 1;9:2714-24.

45. Schabath MB, Hernandez LM, Wu X, Pillow PC, Spitz MR. Dietary phytoestrogens and lung cancer risk. JAMA. 2005 Sep 28;294(12):1493-504.

46. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101(3):485-512.

47. File SE, Jarrett N, Fluck E, et al. Eating soya improves human memory. Psychopharmacology (Berl). 2001 Oct;157(4):430-6.

48. Duffy R, Wiseman H, File SE. Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones. Pharmacol Biochem Behav. 2003 Jun;75(3):721-9.

49. Lee YB, Lee HJ, Sohn HS. Soy isoflavones and cognitive function. J Nutr Biochem. 2005 Nov;16(11):641-9.

50. Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss—a 2 year randomized, placebo-controlled trial. Eur J Nutr. 2004 Aug;43(4):246-57.

51. Zhang X, Shu XO, Li H, et al. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med. 2005 Sep 12;165(16):1890-5.

52. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause. 2000 Jul-Aug;7(4):236-42.

53. Albert A, Altabre C, Baro F, et al. Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: a multicentric, open, prospective and non-randomized trial. Phytomedicine. 2002 Mar;9(2):85-92.

54. Mahady GB, Fabricant D, Chadwick LR, Dietz B. Black cohosh: an alternative therapy for menopause? Nutr Clin Care. 2002 Nov;5(6):283-9.

55. Anon. Cimicifuga racemosa. Monograph. Altern Med Rev. 2003 May;8(2):186-9.

56. Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol. 2005;4(3):177-84.

57. Pockaj BA, Loprinzi CL, Sloan JA, et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest. 2004;22(4):515-21.

58. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol. 2005 Jan;20(1):30-5.

59. Lupu R, Mehmi I, Atlas E, et al. Black cohosh, a menopausal remedy, does not have estrogenic activity and does not promote breast cancer cell growth. Int J Oncol. 2003 Nov;23(5):1407-12.

60. Seidlova-Wuttke D, Hesse O, Jarry H, et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol. 2003 Oct;149(4):351-62.

61. Neff MJ. NAMS releases position statement on the treatment of vasomotor symptoms associated with menopause. Am Fam Physician. 2004 Jul 15;70(2):393-4, 396, 399.

62. Anon. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004 Jan;11(1):11-33.

63. Daniele C, Thompson CJ, Pittler MH, Ernst E. Vitex agnus castus: a systematic review of adverse events. Drug Saf. 2005;28(4):319-32.

64. Blumenthal M. German Federal Institute for Drugs and Medical Devices. Commission E. Herbal Medicine: expanded Commission E monographs. 1st ed. Newton, MA: Integrative Medicine Communications; 2000.

65. Gorkow C, Wuttke W, Marz RW. Effectiveness of Vitex agnus-castus preparations. Wien Med Wochenschr. 2002;152(15-16):364-72.

66. Lauritzen C, Reuter HD, Repges R, Bohnert KJ, Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double-blind study versus pyridoxine. Phytomedicine. 1997;4:183-9.

67. Berger D, Schaffner W, Schrader E, Meier B, Brattstrom A. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet. 2000 Nov;264(3):150-3.

68. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med. 2000 Apr;9(3):315-20.

69. Turner S, Mills S. A double-blind clinical trial on herbal remedy for premenstrual syndrome: a case study. Complement Ther Med. 1993;1:73-7.

70. Halaska M, Raus K, Beles P, Martan A, Paithner KG. Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo. Ceska Gynekol. 1998 Oct;63(5):388-92.

71. Wuttke W, Splitt G, Gorkow C, et al. Treatment of cyclical mastalgia: results of a randomized, placebo-controlled, double-blind study (in Czech). Ceska Gynekol. 1998;63:988-92.

72. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2003 Apr; 18(3):191-5.

73. Jo EH, Kim SH, Ra JC, et al. Chemopreventive properties of the ethanol extract of chinese licorice (Glycyrrhiza uralensis) root: induction of apoptosis and G1 cell cycle arrest in MCF-7 human breast cancer cells. Cancer Lett. 2005 Dec 18;230(2):239-47.

74. Ofir R, Tamir S, Khatib S, Vaya J. Inhibition of serotonin re-uptake by licorice constituents. J Mol Neurosci. 2003 Apr;20(2):135-40.

75. Somjen D, Knoll E, Vaya J, Stern N, Tamir S. Estrogen-like activity of licorice root constituents: glabridin and glabrene, in vascular tissues in vitro and in vivo. J Steroid Biochem Mol Biol. 2004 Jul;91(3):147-55.

76. Choi EM. The licorice root derived isoflavan glabridin increases the function of osteoblastic MC3T3-E1 cells. Biochem Pharmacol. 2005 Aug 1;70(3):363-8.

77. Somjen D, Katzburg S, Vaya J, et al. Estrogenic activity of glabridin and glabrene from licorice roots on human osteoblasts and prepubertal rat skeletal tissues. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):241-6.

78. Yang T, Jia M, Mei Q. Effect of Angelica sinensis polysaccharide on lymphocyte proliferation and cytokine induction. Zhong Yao Cai. 2005 May;28(5):405-7.

79. Tsai NM, Lin SZ, Lee CC, et al. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res. 2005 May 1;11(9):3475-84.

80. Anon. Monograph. Angelica sinensis. Altern Med Rev. 2004 Dec;9(4):429-33.

81. Cheng YL, Chang WL, Lee SC, et al. Acetone extract of Angelica sinensis inhibits proliferation of human cancer cells via inducing cell cycle arrest and apoptosis. Life Sci. 2004 Aug 13;75(13):1579-94.

82. Yang Q, Populo SM, Zhang J, Yang G, Kodama H. Effect of Angelica sinensis on the proliferation of human bone cells. Clin Chim Acta. 2002 Oct;324(1-2):89-97.

83. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997 Dec;68(6):981-6.

84. Chang HM, But PP. Pharmacology and application of chinese material medica. World Scientific. 1987;1:489-505.

85. Kupfersztain C, Rotem C, Fagot R, Kaplan B. The immediate effect of natural plant extract, Angelica sinensis and Matricaria chamomilla (Climex) for the treatment of hot flushes during menopause. A preliminary report. Clin Exp Obstet Gynecol. 2003;30(4):203-6.

86. Chen SW, Min L, Li WJ, et al. The effects of angelica essential oil in three murine tests of anxiety. Pharmacol Biochem Behav. 2004 Oct;79(2):377-82.

87. Fowke JH, Chung FL, Jin F, et al. Urinary isothiocyanate levels, brassica, and human breast cancer. Cancer Res. 2003 Jul 15;63(14):3980-6.

88. Rouzaud G, Young SA, Duncan AJ. Hydrolysis of glucosinolates to isothiocyanates after ingestion of raw or microwaved cabbage by human volunteers. Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):125-31.

89. Anon. Indole-3-carbinol. Monograph. Altern Med Rev. 2005 Dec;10(4):337-42.

90. Kim YS, Milner JA. Targets for indole-3-carbinol in cancer prevention. J Nutr Biochem. 2005 Feb;16(2):65-73.

91. Bradlow HL, Michnovicz JJ, Halper M, et al. Long-term responses of women to indole-3-carbinol or a high fiber diet. Cancer Epidemiol Biomarkers Prev. 1994 Oct;3(7):591-5.

92. Ashok BT, Chen Y, Liu X, et al. Abrogation of estrogen-mediated cellular and biochemical effects by indole-3-carbinol. Nutr Cancer. 2001;41(1-2):180-7.

93. Ashok BT, Chen YG, Liu X, et al. Multiple molecular targets of indole-3-carbinol, a chemopreventive anti-estrogen in breast cancer. Eur J Cancer Prev. 2002 Aug;11 Suppl 2S86-S93.

94. Yuan F, Chen DZ, Liu K, et al. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res. 1999 May;19(3A):1673-80.

95. Liu H, Wormke M, Safe SH, Bjeldanes LF. Indolo[3,2-b]carbazole: a dietary-derived factor that exhibits both antiestrogenic and estrogenic activity. J Natl Cancer Inst. 1994 Dec 7;86(23):1758-65.

96. Riby JE, Xue L, Chatterji U, et al. Activation and Potentiation of Interferon-{gamma} Signaling by 3,3’-Diindolylmethane in MCF-7 Breast Cancer Cells. Mol Pharmacol. 2006 Feb;69(2):430-9.

97. Head KA. Estriol: safety and efficacy. Altern Med Rev. 1998 Apr;3(2):101–13.

98. Taylor M. Unconventional estrogens: estriol, biest, and triest. Clin Obstet Gynecol. 2001 Dec;44(4):864–79.

99. Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998 Nov;28(6):360–9.

100. Stein DG. The case for progesterone. Ann NY Acad Sci. 2005 Jun;1053:152–69.

101. Colson NJ, Lea RA, Quinlan S, MacMillian J, Griffiths LR. Investigation of hormone receptor genes in migraine. Neurogenetics. 2005 Feb;6(1):17–23.

102. Komesaroff PA, Black CV, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001 Jun;4(2):144–50.

103. Uchibayashi M. Forgotten episodes of the birth of cortisone. Yakushigaku Zasshi. 2001;36(1):70–5.

104. Williams GH, Dluhy RG. Disorders of the adrenal cortex. In: Harrison’s Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001.

105. Khorram O. DHEA: a hormone with multiple effects. Curr Opin Obstet Gynecol. 1996;8(5):351–4.

106. Wilder RL. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. J Rheumatol Suppl. 1996 Mar;44:10–2.

107. Berkman LF, Seeman TE, Albert M, et al. High, usual and impaired functioning in community-dwelling older men and women: findings from the MacArthur Foundation Research Network on Successful Aging. J Clin Epidemiol. 1993 Oct;46(10):1129–40.

108. Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies. J Clin Pharmacol. 2002 Mar;42(3):247–66.

109. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol. 1999 Apr;39(4):327–48.

110. Proctor DN, Balagopal P, Nair KS. Age-related sarcopenia in humans is associated with reduced synthetic rates of specific muscle proteins. J Nutr. 1998 Feb;128(2 Suppl):351S–5S.

111. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. Potential remedial effects. Ann NY Acad Sci. 1995 Dec 29;774:128–42.

112. Rupprecht R, Holsboer F. Neuropsychopharmacological properties of neuroactive steroids. Steroids. 1999 Jan;64(1–2):83–91.

113. Casson PR, Faquin LC, Stentz FB, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995 May;63(5):1027–31.

114. Schneider HP. Androgens and antiandrogens. Ann NY Acad Sci. 2003 Nov; 997:292-306.

115. Burd ID, Bachmann GA. Androgen replacement in menopause. Curr Womens Health Rep. 2001 Dec;1(3):202-5.

116. Watt PJ, Hughes RB, Rettew LB, Adams R. A holistic programmatic approach to natural hormone replacement. Fam Community Health. 2003 Jan;25(1):53-63.

117. Bachmann GA. Androgen therapy in menopause: evolving benefits and challenges. Am J Obstet Gynecol. 1999 Mar;180(3 Pt 2):308-11.

118. Braunstein GD. Androgen insufficiency in women: summary of critical issues. Fertil Steril. 2002 Apr;77(Suppl 4):S94–9.

119. Cameron DR, Braunstein GD. Androgen replacement therapy in women. Fertil Steril. 2004 Aug;82(2):273-89.

120. Davis A, Gilbert K, Misiowiec P, Riegel B. Perceived effects of testosterone replacement therapy in perimenopausal and postmenopausal women: an internet pilot study. Health Care Women Int. 2003 Nov;24(9):831–48.

121. Havlikova H, Hill M, Hampl R, Starka L. Sex- and age-related changes in epitestosterone in relation to pregnenolone sulfate and testosterone in normal subjects. J Clin Endocrinol Metab. 2002 May;87(5):2225-31.

122. Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nabeshima T. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol. 1999 Oct;81(2):125–55.

123. Yao ZX, Brown RC, Teper G, Greeson J, Papadopoulos V. 22R-Hydroxycholesterol protects neuronal cells from beta-amyloid-induced cytotoxicity by binding to beta-amyloid peptide. J Neurochem. 2002 Dec;83(5):1110–19.

124. Kelly JP, Kaufman DW, Rosenberg L, et al. Use of postmenopausal hormone therapy since the Women’s Health Initiative findings. Pharmacoepidemiol Drug Saf. 2005 Dec;14(12):837-42.